Minocycline: Neuroprotective Mechanisms in Parkinsons Disease

Author(s): M. Thomas, W. D. Le

Journal Name: Current Pharmaceutical Design

Volume 10 , Issue 6 , 2004

Become EABM
Become Reviewer


Parkinsons disease (PD) is a common neurodegenerative disorder characterized by cardinal features of tremor, bradykinesia, rigidity and postural instability. In addition to the motor symptoms patients experience cognitive decline eventually resulting in severe disability. Pathologically PD is characterized by neurodegeneration in the substantia nigra pars compacta (SNc) with intracytoplasmic inclusions known as Lewy bodies. In addition to the SNc there is neurodegeneration in other areas including cerebral cortex, raphe nuclei, locus ceruleus, nucleus basalis of meynert, cranial nerves and autonomic nervous system. Recent evidence supports the role of inflammation in Parkinsons disease. Apoptosis has been shown to be one of the pathways of cell death in PD. Minocycline, a tetracycline derivative is a caspase inhibitor, and also inhibits the inducible nitric oxide synthase which are important for apoptotic cell death. Furthermore, Minocycline has been shown to block microglial activation of 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonism animal models and protect against nigrostriatal dopaminergic neurodegeneration. In this review, we present the current experimental evidence for the potential use of tetracycline derivative, minocycline, as a neuroprotective agent in PD.

Keywords: tetracycline derivatives, minocycline, parkinsons disease, neuroprotection, dopamine, microglia, apoptosis, caspase

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2004
Page: [679 - 686]
Pages: 8
DOI: 10.2174/1381612043453162
Price: $65

Article Metrics

PDF: 7